Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis

Tempus AI, Inc. (Nasdaq: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced that it has entered into a definitive agreement to acquire Personalis, Inc. (Nasdaq: PSNL). The acquisition will expand Tempus AI's capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.

Latham & Watkins LLP advised Tempus AI in the transaction with a corporate team led by partners Bradley Faris, Tessa Bernhardt, and Jana Kovich, with associates Ziyad Barghouthy, Matthew Galligan, David Lee, Liem-Lucas Nguyen, Graham Core, and E.B. Nasir. Advice was also provided on capital markets matters by partner Cathy Birkeland, with associates Kenneth Sands, Andrew Rutsky, and Nat Lewis; on compensation and benefits matters by partner Ashley Wagner, with associate Julia Lee; on tax matters by partner Rene de Vera, with associate Jorge Hinzpeter; on labor and employment matters by partner Nineveh Alkhas, with associate Jocelyn Wexler; on intellectual property matters by counsel Arielle Singh, with associate Karen Lee; on intellectual property litigation matters by partner Herman Yue; on data privacy and cybersecurity matters by partner Heather Deixler, with associates Zac Alpert and Ryleigh Chen; on healthcare regulatory matters by partner Betty Pang, with counsel Yanyan Zhou and associate Margaret Rote; on FDA regulatory matters by partner Elizabeth Richards, with associate Evan Miller; on antitrust matters by partners Kelly Fayne, Ian Conner, and Patrick English, with associate Nathaniel Amann; on US securities laws matters by partners Michele Anderson and William Hackett, with associate Sara Almousa; on Nasdaq related matters by partner Gail Neely; and on securities litigation matters by partner Nicholas Siciliano, with associate Matthew Strand.